An Open Label Study for Participants With Rheumatoid Arthritis
Status:
Terminated
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to help answer if LY2127399 is safe and effective during
long-term treatment in participants with Rheumatoid Arthritis.
This study is comprised of 2 periods:
Period 1: Unblinded treatment for up to 240 weeks for participants who enroll from Study
H9B-MC-BCDO (BCDO) (NCT01202760) or Study H9B-MC-BCDV (BCDV) (NCT01202773) or up to 168 weeks
for participants who enroll from Study H9B-MC-BCDM (BCDM) (NCT01198002).
Period 2: 48-week post-treatment follow-up